Trial reportBritish journal of sports medicine2004
Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
Trial report in British journal of sports medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Nandrolone Decanoate: Use, Abuse and Side Effects.Medicina (Kaunas, Lithuania) · 2020Pooled it
- National Athletic Trainers' Association position statement: anabolic-androgenic steroids.Journal of athletic trainingGuideline
- Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers.Clinical cardiology · 2026Review
- Impact of Anabolic-Androgenic Steroid Abuse on the Cardiovascular System: Molecular Mechanisms and Clinical Implications.International journal of molecular sciences · 2025Review
- Anabolic-Androgenic Steroids Induced Cardiomyopathy: A Narrative Review of the Literature.Biomedicines · 2025Review
- High-density lipoprotein (HDL) as an indicator for alcohol use in a psychiatrically ill population.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Observational
- Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Association of vitamins, minerals, and lead with lipoprotein(a) in a cross-sectional cohort of US adults.International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition · 2023Article
- Anabolic androgenic steroids and cardiomyopathy: an update.Frontiers in cardiovascular medicine · 2023Review
- Management of Dyslipidemia in Endocrine Diseases.Endocrinology and metabolism clinics of North America · 2022Review
- Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes.Scandinavian journal of medicine & science in sports · 2022Article
- Anabolic androgenic steroid-induced liver injury: An update.World journal of gastroenterology · 2022Review
- Non-genetic influences on lipoprotein(a) concentrations.Atherosclerosis · 2022Review
- Crosstalk between high-density lipoproteins and endothelial cells in health and disease: Insights into sex-dependent modulation.Frontiers in cardiovascular medicine · 2022Review
- Dietary Supplements as Source of Unintentional Doping.BioMed research international · 2022Review
- Anabolic-androgenic steroids: How do they work and what are the risks?Frontiers in endocrinology · 2022Review
- Understanding exercise addiction, psychiatric characteristics and use of anabolic androgenic steroids among recreational athletes - An online survey study.Frontiers in sports and active living · 2022Article
- Severe Cardiac and Metabolic Pathology Induced by Steroid Abuse in a Young Individual.Diagnostics (Basel, Switzerland) · 2021Article
- How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health.Reviews in endocrine & metabolic disorders · 2021Review
- Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes.
methodsIn a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined.
resultsIn study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l. Serum Lp(a) declined from 189 (315) to 32 (63) U/l. Total cholesterol and triglycerides did not change significantly. Alterations after eight and 14 weeks of AAS administration were comparable. No changes occurred in the controls. Six weeks after AAS cessation, serum HDL-C, HDL2-C, Apo-A1, Apo-B, and Lp(a) had still not returned to baseline concentrations. Administration of AAS for 14 weeks was associated with slower recovery to pretreatment concentrations than administration for eight weeks. In study 2, nandrolone decanoate did not influence serum triglycerides, total cholesterol, HDL-C, HDL2-C, HDL3-C, Apo-A1, and Apo-B concentrations after four and eight weeks of intervention, nor six weeks after withdrawal. However, Lp(a) concentrations decreased significantly from 103 (68) to 65 (44) U/l in the nandrolone decanoate group, and in the placebo group a smaller reduction from 245 (245) to 201 (194) U/l was observed. Six weeks after the intervention period, Lp(a) concentrations had returned to baseline values in both groups.
conclusionsSelf administration of several AASs simultaneously for eight or 14 weeks produces comparable profound unfavourable effects on lipids and lipoproteins, leading to an increased atherogenic lipid profile, despite a beneficial effect on Lp(a) concentration. The changes persist after AAS withdrawal, and normalisation depends on the duration of the drug abuse. Eight weeks of administration of nandrolone decanoate does not affect lipid and lipoprotein concentrations, although it may selectively reduce Lp(a) concentrations. The effect of this on atherogenesis remains to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.